A5018031262- Mesenchymal stem cell research
- Tissue Engineering and Regenerative Medicine
- Renal and Vascular Pathologies
- MicroRNA in disease regulation
- Polyomavirus and related diseases
- Hydrogen's biological and therapeutic effects
- Nephrotoxicity and Medicinal Plants
- Cardiovascular Disease and Adiposity
- Congenital Heart Disease Studies
- Adipose Tissue and Metabolism
- Renal Transplantation Outcomes and Treatments
- Complement system in diseases
- Cancer, Hypoxia, and Metabolism
- Multiple Myeloma Research and Treatments
- Adenosine and Purinergic Signaling
- Cancer Immunotherapy and Biomarkers
- Diagnosis and treatment of tuberculosis
- Renal Diseases and Glomerulopathies
- Pneumocystis jirovecii pneumonia detection and treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Respiratory Support and Mechanisms
- Ethics in Clinical Research
- Lung Cancer Treatments and Mutations
- Acute Kidney Injury Research
- Airway Management and Intubation Techniques
Hypertension Institute
2025
Nazareth Hospital
2023-2024
Mayo Clinic
2021-2024
WinnMed
2021-2023
Abstract Background Atherosclerotic renal artery stenosis (ARAS) is a risk factor for ischemic and hypertensive kidney disease (HKD) which autologous mesenchymal stem cell (MSC) appears to be promising therapy. However, MSCs from ARAS patients exhibit impaired function, senescence, DNA damage, possibly due epigenetic mechanisms. Hypoxia preconditioning (HPC) exerts beneficial effects on cellular proliferation, differentiation, gene protein expression. We hypothesized that HPC could influence...
Abstract Background Autologous mesenchymal stem cells (MSCs) have emerged as a therapeutic option for many diseases. Hypertensive kidney disease (HKD) might impair MSCs’ reparative ability by altering the biomolecular properties, but characteristics of this impairment are unclear. In our previous pre-clinical studies, we found hypoxic preconditioning (HPC) enhanced angiogenesis and suppressed senescence gene expression. Thus, hypothesize that HPC would improve human MSCs enhancing their...
Abstract Background and Hypothesis Teclistamab, a novel bispecific monoclonal antibody targeting CD3 B-cell maturation antigen (BCMA), chimeric receptor T-cell (CAR-T) therapy are promising options for treating relapsed/refractory multiple myeloma (MM). However, the rates of acute kidney injury (AKI) associated with teclistamab remain inadequately characterized. This study aims to compare incidence, severity, outcomes AKI between patients receiving CAR-T therapy. Methods was retrospective...
Atherosclerotic renal artery stenosis (ARAS) is associated with irreversible parenchymal disease and regenerative stem cell therapies may improve outcomes. Hypoxia preconditioning (HPC) the functions of adipose tissue-derived mesenchymal cells (AMSC) by affecting DNA 5-hydroxymethylcytosine (5hmC) marks in angiogenic genes. Here, we investigated using a porcine ARAS model, whether growth AMSCs hypoxia (Hx) versus normoxia (Nx) would enhance tissue repair, comprehensively analyze how HPC...
Journal Article Accepted manuscript Biomarker Guided Infliximab Therapy for Immune Checkpoint Inhibitor-induced Acute Interstitial Nephritis Get access Elena-Bianca Barbir, Barbir Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA https://orcid.org/0000-0001-8146-0268 Search other works by this author on: Oxford Academic PubMed Google Scholar Arjunmohan Mohan, Mohan Priscilla Koirala, Koirala Luis E Gutierrez, Gutierrez Callen D Giesen, Giesen Clinical Core...
ABSTRACT We report a case of acute interstitial nephritis (AIN) in 68-year-old male with squamous cell carcinoma (SCC) and relapsed/refractory multiple myeloma (RRMM) who developed kidney injury (AKI) shortly after starting teclistamab for RRMM. Despite stable renal function on immune checkpoint inhibitor (ICI) therapy SCC, proton pump inhibitors trimethoprim-sulfamethoxazole 3 years, AKI only occurred post-teclistamab initiation. Biopsy-confirmed AIN serum creatinine improved pulse-dose...
Abstract Background and Aims Autologous mesenchymal stem/stromal cells (MSCs) have emerged as a therapeutic option for many chronic diseases. Hypertensive kidney disease (HKD) might impair MSCs’ reparative ability by altering important biomolecular properties of the cell, but characteristics this impairment are unclear. In our previous pre-clinical studies, hypoxic preconditioning (HPC) enhanced MSC angiogenesis reduced senescence through global gene protein expression. Thus, we hypothesize...
Sohi, Gurparneet K.; Kazeminia, Sara; Mohan, Arjunmohan; Farooqui, Naba; Eirin, Alfonso; Lerman, Lilach O.; Herrmann, Sandra Author Information
Abstract Background and Aims While the percentage of women entering nephrology has increased over years, representation sex disparities in authorship major Clinical practice guidelines (CPG) not been examined. Our study evaluates current representation, nationalities authors CPGs developed by Kidney Disease: Improving Global Outcomes (KDIGO), Disease Quality Initiative (KDOQI), European Renal Best Practice (ERBP), official guideline body ERA-EDTA. Method We examined number female versus male...
Mohan, Arjunmohan; Farooqui, Naba; Isik, Busra; Zhu, Xiang yang; Jordan, Kyra L.; Saadiq, Ishran M.; Tang, Hui; Hickson, LaTonya J.; Textor, Stephen C.; Eirin, Alfonso; Lerman, Lilach O.; Herrmann, Sandra Author Information
Farooqui, Naba; Mohan, Arjunmohan; Zhu, Xiang yang; Saadiq, Ishran M.; Ferguson, Christopher Jordan, Kyra L.; Tang, Hui; Textor, Stephen C.; Hickson, LaTonya J.; Eirin, Alfonso; Lerman, Lilach O.; Herrmann, Sandra Author Information